Antitumor mechanism of antisense cantide targeting human telomerase reverse transcriptase

World Journal of Gastroenterology

Volumn 9, Issue 9, 2003, Pages 2030-2035

  Du, Qing You ^a   Wang, Xiao Bo ^a   Chen, Xue Jun ^b   Zheng, Wei ^b   Wang, Sheng Qi ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CANTIDE; CASPASE 3; ENZYME; INTERLEUKIN 1BETA CONVERTING ENZYME; LIPOFECTIN; MESSENGER RNA; PROTEINASE; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER THERAPY; CELL ASSAY; CELL STRAIN HEPG2; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CULTURE MEDIUM; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; FETAL CALF SERUM; HUMAN; HUMAN CELL; INHIBITION KINETICS; LIVER CELL CARCINOMA; MONOTHERAPY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; WESTERN BLOTTING;

EID: 0141718413     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v9.i9.2030     Document Type: Article

References (31)

1. Holt SE, Shay JW. Role of telomerase in cellular proliferation and cancer. J Cell Physiol 1999; 180: 10-18
2. Shen ZY, Xu LY, Li EM, Cai WJ, Chen MH, Shen J, Zeng Y. Telomere and telomerase in the initial stage of immortalization of esophageal epithelial cells. World J Gastroenterol 2002; 8: 357-362
3. Granger MP, Wright WE, Shay JW. Telomerase in cancer and aging. Crit Rev Oncol Hematol 2002; 41: 29-40
4. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33: 787-791
5. Kim NW. Clinical implications of telomerase in cancer. Eur J Cancer 1997; 33: 781-786
6. Helder MN, Jong S, Vries EG, Zee AG. Telomerase targeting in cancer treatment: New developments. Drug Resist Updat 1999; 2: 104-115
7. Stewart SA, Weinberg RA. Telomerase and human tumorigenesis. Semin Cancer Biol 2000; 10: 399-406
8. Blackburn EH. Switching and signaling at the telomere. Cell 2001; 106: 661-673
9. Wang X, Zhang Z, Xu Y, Chen S, Xiong W. Inhibition of telomerase activity and induction of apoptosis in lung cancer cell by human telomerase reverse transcriptase gene antisense oligodeoxynucleotide. Zhonghua Neike Zazhi 2002; 41: 175-178
10. Adah SA, Bayly SF, Cramer H, Silverman RH, Torrence PF. Chemistry and biochemistry of 2′, 5′-oligoadenylate-based antisense strategy. Curr Med Chem 2001; 8: 1189-1212
11. Mukai S, Kondo Y, Koga S, Komata T, Barna BP, Kondo S. 2-5A antisense telomerase RNA therapy for intracranial malignant gliomas. Cancer Res 2000; 60: 4461-4467
12. Koga S, Kondo Y, Komata T, Kondo S. Treatment of bladder cancer cells in vitro and in vivo with 2-5A antisense telomerase RNA. Gene Ther 2001; 8: 654-658
13. Ulaner GA, Hu JF, Vu TH, Giudice LC, Hoffman AR. Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res 1998; 58: 4168-4172
14. Zhu H, Fu W, Mattson MP. The catalytic subunit of telomerase protects neurons against amyloid beta-peptide-induced apoptosis. J Neurochem 2000; 75: 117-124
15. Wang SQ, Lin L, Chen ZD, Lin RX, Chen SH, Guan W, Wang XH. Effect of antisense oligonucleotides targeting telomerase catalytic subunit on tumor cell proliferation in vitro. Chinese Sci Bulletin 2002; 47: 993-997
16. Green DW, Roh H, Pippin J, Drebin JA. Antisense oligonucleotides: An evolving technology for the modulation of gene expression in human disease. J Am Coll Surg 2000; 191: 93-105
17. Counter SM, Meyerson M, Eaton EN, Ellisen LW, Caddle SD, Haber DA, Weinberg RA. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene 1998; 16: 1217-1222
18. Chang JT, Chen YL, Yang HT, Chen CY, Cheng AJ. Differential regulation of telomerase activity by six telomerase subunits. Eur J Biochem 2002; 269: 3442-3450
19. Takahashi A. Caspase: Executioner and undertaker of apoptosis. Int J Hematol 1999; 70: 226-232.
20. Habn WC, Meyerson M. Telomerase activation, cellular immortalization and cancer. Ann Med 2001; 33: 123-129
21. Yang Y, Chen Y, Zhang C, Huang H, Weissman SM. Nucleolar localization of hTERT protein is associated with telomerase function. Exp Cell Res 2002; 277: 201-209
22. Klingelhultz AJ. The roles of telomeres and telomerase in cellular immortalization and the development of cancer. Anticancer Res 1999; 19: 4823-4830
23. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, Adams RR, Chang E, Allsopp RC, Yu J, Le S, West MD, Harley CB, Andrew WH, Greider CW, Villeponteau B. The RNA component of human telomerase. Science 1995; 269: 1236-1241
24. White LK, Wright WE, Shay JW. Telomerase inhibitors. Trends Biotech 2001; 19: 114-120
25. Kondo Y, Koga S, Komata T, Kondo S. Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component. Oncogene 2000; 19: 2205-2211
26. Kumar S. Regulation of caspase activation in apoptosis: Implications in pathogenesis and treatment of disease. Clin Exp Pharmacol Physiol 1999; 26: 295-303
27. Shi Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell 2002; 9: 459-470
28. Van De Craen M, Van Loo G, Pype S, Van Criekinge W, Van Den Drande I, Molemans F, Fiers W, Declercq W, Vandenabeele P. Identification of a new caspase homologue: Caspase-14. Cell Death Differ 1998; 5: 838-846
29. Kushner DM, Paranjape JM, Bandyopadhyay B, Cramer H, Leaman DW, Kennedy AW, Silverman RH, Cowell JK. 2-5A antisense directed against telomerase RNA produces apoptosis in ovarian cancer cells. Gynecol Oncol 2000; 76: 183-192
30. Ren JG, Xia HL, Tian YM, Just T, Cai JP, Dai YR. Expression of telomerase inhibits hydroxyl radical-induced apoptosis in normal telomerase negative human lung fibroblasts. FEBS Lett 2001; 488: 133-138
31. Cao Y, Li H, Mu FT, Ebisui O, Funder JW, Liu JP. Telomerase activation causes vascular smooth muscle cell proliferation in genetic hypertension. FASEB J 2002; 16: 96-98